Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the early virological response (EVR = undetectable
[ribonucleic acid-hepatitis C virus] RNA-HCV or a reduction of > 2 log10) of patients with
chronic hepatitis C coinfected with HIV treated with induction doses of peginterferon
alpha-2a (40 KD) 270 µg/week and ribavirin 1600 mg/day for 4 weeks, followed by 8 weeks of
treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day
versus treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200
mg/day for 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborators:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia